Title : Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes.

Pub. Date : 2019 Oct

PMID : 31440988






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Given the results from recent studies, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommend that patients with T2D and clinical cardiovascular disease (CVD) with inadequate glucose control despite treatment with metformin should receive an SGLT2 inhibitor or GLP-1 receptor agonist. Metformin glucagon like peptide 1 receptor Homo sapiens